Disease Site-Specific Outcomes in p16-Positive Non-Oropharyngeal Mucosal Head and Neck Cancer - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Outcomes Based on Disease Site in p16-Positive Non-Oropharyngeal Mucosal Head and Neck Squamous Cell Carcinoma

  • By

  • Revadhi C. Chelvarajah

  • Lessandra Y. S. Chee

  • Jie Su

  • Brian O'Sullivan

  • Christopher M. K. L. Yao

  • Enrique Sanz-Garcia

  • Stephen M. Smith

  • Ilan Weinreb

  • Scott Bratman

  • B. C. John Cho

  • Ezra Hahn

  • Andrew Hope

  • Ali Hosni

  • John Kim

  • Andrew McPartlin

  • Nauman Malik

  • Chiaojung Jillian Tsai

  • John de Almeida

  • Anna Spreafico

  • Li Tong

  • Shao Hui Huang

  • John N Waldron

  • March 12, 2026

Share

  • 1

    The study investigates the prevalence and prognostic significance of p16-positive status in non-oropharyngeal head and neck squamous cell carcinoma (HNSCC).

  • 2

    A total of 3061 non-oropharyngeal HNSCC cases were identified, with p16 testing performed on 466 patients, revealing 91 p16-positive cases.

  • 3

    The study found varying outcomes associated with p16 positivity, with some studies reporting improved survival in laryngeal and hypopharyngeal cancers.

  • 4

    Testing methodologies for p16 and HPV varied, impacting the interpretation of survival benefits in non-oropharyngeal HNSCC.

  • 5

    The research was conducted at a tertiary cancer center, utilizing a comprehensive database to assess p16-positive non-oropharyngeal HNSCC outcomes.

Original Source(s)

Related Content